[go: up one dir, main page]

WO2004060270A8 - Compositions et methodes pour diagnostiquer et traiter des tumeurs - Google Patents

Compositions et methodes pour diagnostiquer et traiter des tumeurs

Info

Publication number
WO2004060270A8
WO2004060270A8 PCT/US2003/029126 US0329126W WO2004060270A8 WO 2004060270 A8 WO2004060270 A8 WO 2004060270A8 US 0329126 W US0329126 W US 0329126W WO 2004060270 A8 WO2004060270 A8 WO 2004060270A8
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
diagnosis
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/029126
Other languages
English (en)
Other versions
WO2004060270A2 (fr
Inventor
Thomas D Wu
Yan Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to AU2003303144A priority Critical patent/AU2003303144A1/en
Priority to EP03813488A priority patent/EP1578996A4/fr
Priority to JP2004564724A priority patent/JP2006516192A/ja
Priority to CA002503043A priority patent/CA2503043A1/fr
Publication of WO2004060270A2 publication Critical patent/WO2004060270A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004060270A8 publication Critical patent/WO2004060270A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2003/029126 2002-10-18 2003-10-15 Compositions et methodes pour diagnostiquer et traiter des tumeurs Ceased WO2004060270A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003303144A AU2003303144A1 (en) 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor
EP03813488A EP1578996A4 (fr) 2002-10-18 2003-10-15 Compositions et methodes pour diagnostiquer et traiter des tumeurs
JP2004564724A JP2006516192A (ja) 2002-10-18 2003-10-15 腫瘍の診断と治療のための組成物と方法
CA002503043A CA2503043A1 (fr) 2002-10-18 2003-10-15 Compositions et methodes pour diagnostiquer et traiter des tumeurs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41898802P 2002-10-18 2002-10-18
US60/418,988 2002-10-18

Publications (2)

Publication Number Publication Date
WO2004060270A2 WO2004060270A2 (fr) 2004-07-22
WO2004060270A8 true WO2004060270A8 (fr) 2005-07-14

Family

ID=32712943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/029126 Ceased WO2004060270A2 (fr) 2002-10-18 2003-10-15 Compositions et methodes pour diagnostiquer et traiter des tumeurs

Country Status (5)

Country Link
EP (1) EP1578996A4 (fr)
JP (1) JP2006516192A (fr)
AU (1) AU2003303144A1 (fr)
CA (1) CA2503043A1 (fr)
WO (1) WO2004060270A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1468118A4 (fr) * 2002-01-31 2006-08-02 Millennium Pharm Inc Procedes et compositions pour le traitement du cancer
AU2003226131A1 (en) 2002-03-28 2003-10-13 Bristol-Myers Squibb Company Novel human cell surface protein with immunoglobulin folds, bgs-19
EP1576096A4 (fr) * 2002-04-23 2007-05-23 Univ Georgia Res Found Sequence de codage de n-acetylglucosaminyltransferase vb, cellules recombinantes et procedes associes
JP2005230011A (ja) * 2004-02-20 2005-09-02 Samsung Electronics Co Ltd 乳ガン関連蛋白質、それをコーディングする遺伝子、及び該蛋白質及び該遺伝子を利用した乳ガンの診断方法
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7741299B2 (en) 2004-08-16 2010-06-22 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of RTP801
GB0422211D0 (en) * 2004-10-06 2004-11-03 Randox Lab Ltd Method
KR20070090156A (ko) * 2004-10-13 2007-09-05 에이 앤드 지 파마슈티컬즈, 인코포레이티드 오토크라인 성장 인자 수용체 및 방법
JP2007008844A (ja) * 2005-06-29 2007-01-18 Nippon Flour Mills Co Ltd セプチン2タンパク質と特異的に反応するモノクローナル抗体、それを産生するハイブリドーマ、癌の検出方法及び癌の検出用キット
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
WO2008054534A2 (fr) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Systèmes de criblage utilisant le rtp801
IL282783B2 (en) * 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
WO2007141796A2 (fr) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Utilisations thérapeutiques d'inhibiteurs de rtp801l
JP2010518880A (ja) 2007-02-26 2010-06-03 クアーク・ファーマスーティカルス、インコーポレイテッド Rtp801のインヒビター及びその疾患の治療における使用
WO2008148072A2 (fr) * 2007-05-24 2008-12-04 The Brigham And Women's Hospital, Inc. Variations genetiques liees a une maladies et methodes de detection et d'utilisation de ces variations
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
JP2012501167A (ja) * 2008-08-27 2012-01-19 オンコセラピー・サイエンス株式会社 膵臓癌関連遺伝子ttll4
KR20110128316A (ko) 2009-02-20 2011-11-29 가니메드 파마슈티칼스 아게 암의 진단 및 치료를 위한 방법 및 조성물
NZ734307A (en) 2009-11-11 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
WO2011150400A1 (fr) * 2010-05-28 2011-12-01 New York Blood Center, Inc. Protéine de support nucléaire stip/tfip11 au titre de cible pour la thérapie anticancéreuse
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
CN107011440B (zh) 2011-05-13 2021-03-05 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
AP2015008365A0 (en) 2012-12-05 2015-04-30 Novartis Ag Compositions and methods for antibodies targeting epo
ES2670529T3 (es) * 2013-03-15 2018-05-30 Translate Bio, Inc. Mejora sinergística de la entrega de ácidos nucleicos a través de formulaciones mezcladas
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
ES2913530T3 (es) 2015-08-12 2022-06-02 Novartis Ag Métodos para tratar trastornos oftálmicos
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP4295904A3 (fr) 2017-05-24 2024-02-28 Thoeris GmbH Utilisation de glutamine synthétase pour le traitement de l'hyperammoniémie
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
BR112021004670A2 (pt) 2018-09-28 2021-06-01 President And Fellows Of Harvard College reprogramação celular para reverter o envelhecimento e promover a regeneração de órgãos e tecidos
JP7766904B2 (ja) * 2021-06-04 2025-11-11 地方独立行政法人東京都健康長寿医療センター 前立腺がん治療用医薬組成物
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445317A3 (fr) * 2000-08-24 2004-12-15 Genentech Inc. Compositions et procédés de diagnostic et traitement de tumeurs
KR20040014392A (ko) * 2000-08-24 2004-02-14 제넨테크, 인크. 종양의 진단 및 치료용 조성물 및 방법
MXPA03001643A (es) * 2000-08-24 2004-05-14 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.

Also Published As

Publication number Publication date
EP1578996A4 (fr) 2007-12-19
JP2006516192A (ja) 2006-06-29
WO2004060270A2 (fr) 2004-07-22
EP1578996A2 (fr) 2005-09-28
AU2003303144A1 (en) 2004-07-29
CA2503043A1 (fr) 2004-07-22

Similar Documents

Publication Publication Date Title
WO2004030615A8 (fr) Compositions et procedes de diagnostic et de traitement de tumeur
EP1571968A3 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
WO2004016225A8 (fr) Compositions et methodes de diagnostic et de traitement des tumeurs
WO2004045516A9 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
EP1572091A3 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
WO2004060270A8 (fr) Compositions et methodes pour diagnostiquer et traiter des tumeurs
WO2003057160A8 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur
IL165950A0 (en) Compositions and method for the diagnosis and treatment of tumor
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003072035A8 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
WO2004041170A9 (fr) Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
WO2004024097A9 (fr) Compositions et methodes de traitement de maladies de nature immune
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2003286741A1 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
AU2003290605A1 (en) Compositions and methods for the diagnosis and treatment of sepsis
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2005003154A8 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003303144

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003813488

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2503043

Country of ref document: CA

Ref document number: 2004564724

Country of ref document: JP

D17 Declaration under article 17(2)a
WWP Wipo information: published in national office

Ref document number: 2003813488

Country of ref document: EP